Discovery of Novel 2,4-Dianilinopyrimidine Derivatives Containing 4-(Morpholinomethyl)phenyl and
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Benzamides
/ chemistry
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Drug Design
Drug Screening Assays, Antitumor
/ methods
Focal Adhesion Protein-Tyrosine Kinases
/ antagonists & inhibitors
Humans
Molecular Docking Simulation
Molecular Structure
Morpholines
/ pharmacology
Neoplasms
/ drug therapy
Phenols
/ chemistry
Protein Kinase Inhibitors
/ pharmacology
Pyrimidines
/ chemistry
Structure-Activity Relationship
2,4-dianilinopyrimidine
4-(morpholinomethyl)phenyl
FAK inhibitor
N-substituted benzamides
anticancer
molecular docking
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
09 Jul 2021
09 Jul 2021
Historique:
received:
11
06
2021
revised:
06
07
2021
accepted:
06
07
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
21
9
2021
Statut:
epublish
Résumé
Focal adhesion kinase (FAK) is responsible for the development and progression of various malignancies. With the aim to explore novel FAK inhibitors as anticancer agents, a series of 2,4-dianilinopyrimidine derivatives
Identifiants
pubmed: 34299462
pii: molecules26144187
doi: 10.3390/molecules26144187
pmc: PMC8304610
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Benzamides
0
Morpholines
0
Phenols
0
Protein Kinase Inhibitors
0
Pyrimidines
0
TAE226
0
morpholinomethylphenol
54804-09-0
Focal Adhesion Protein-Tyrosine Kinases
EC 2.7.10.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 21402012; 21907010
Organisme : Natural Science Foundation of Shanxi Province
ID : 201901D211465
Références
Cancer Res. 2008 Mar 15;68(6):1935-44
pubmed: 18339875
Mol Oncol. 2012 Apr;6(2):155-76
pubmed: 22440008
PLoS One. 2008;3(11):e3800
pubmed: 19030106
Am J Pathol. 2004 Oct;165(4):1087-95
pubmed: 15466376
J Med Chem. 2017 Sep 28;60(18):7617-7635
pubmed: 28505442
Cell Cycle. 2014;13(19):3143-9
pubmed: 25486573
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nature. 2014 Oct 2;514(7520):112-6
pubmed: 25079333
Nat Rev Cancer. 2013 Oct;13(10):714-26
pubmed: 24060863
Clin Cancer Res. 2000 Jun;6(6):2417-23
pubmed: 10873094
Exp Cell Res. 2011 May 1;317(8):1134-46
pubmed: 21338601
Eur J Med Chem. 2020 Feb 15;188:112024
pubmed: 31923858
Cell. 2015 Sep 24;163(1):160-73
pubmed: 26406376
Cancer Discov. 2014 Sep;4(9):1046-61
pubmed: 24893891
Ann Surg Oncol. 1996 Jan;3(1):100-5
pubmed: 8770310
Cancer J. 2003 Mar-Apr;9(2):126-33
pubmed: 12784878
Nat Commun. 2013;4:2020
pubmed: 23799510
Nat Med. 2016 Aug;22(8):851-60
pubmed: 27376576
Int J Cancer. 1996 Oct 9;68(2):164-71
pubmed: 8900422
J Med Chem. 2016 Aug 25;59(16):7478-96
pubmed: 27527804
J Med Chem. 2020 Dec 10;63(23):14382-14403
pubmed: 33058670
Prostate. 2018 Mar;78(4):308-317
pubmed: 29314097
Lung Cancer. 2006 Sep;53(3):263-71
pubmed: 16842883
Oncogenesis. 2018 Sep 20;7(9):73
pubmed: 30237500
Cancer Biol Ther. 2010 May 15;9(10):778-90
pubmed: 20234193
J Histochem Cytochem. 2015 Feb;63(2):114-28
pubmed: 25380750
Nat Rev Cancer. 2009 Jan;9(1):28-39
pubmed: 19104514
J Med Chem. 2013 Apr 11;56(7):2975-90
pubmed: 23517371
Arch Ophthalmol. 1996 Nov;114(11):1348-56
pubmed: 8906025
J Cancer Res Clin Oncol. 2010 Oct;136(10):1489-96
pubmed: 20151150
Elife. 2019 Sep 03;8:
pubmed: 31478830
Hum Pathol. 2010 Dec;41(12):1664-73
pubmed: 20869748